Bret Stephens, PhD
Director, R&D

Dr. Stephens is a research scientist with a broad background in molecular and cell biology that comes from over a decade of involvement in drug discovery and development in both academic and pharmaceutical industry settings. Dr. Stephens received a B.S. degree in Plant Science from Utah State University, and earned his PhD degree from the University of Arizona in Molecular Biology. Previous to joining Wasatch Scientific, Dr. Stephens worked at the BioDesign Institute (Arizona State University), Huntsman Cancer Institute (University of Utah), and Tolero Pharmaceuticals, where he focused on epigenetics, assay development, and small molecule drug development.

Marc Oddou
Business Operations & Development

Mr. Oddou has valuable experience in the scientific and business sides of the biotech industry. After completing a degree in biotechnology from Brigham Young University, Mr. Oddou helped launch Frost Biologic, an early stage drug discovery company. Mr. Oddou later worked as a biotechnology analyst in San Diego, and as an associate at the Center for Investigational Therapeutics at the Huntsman Cancer Institute. Marc earned an MBA at the University of Utah where he served as a fellow at the Pierre Lassonde Entrepreneur Institute.



Adam Siddiqui-Jain, PhD
Medicinal Chemistry

Dr Siddiqui-Jain holds a PhD in medicinal chemistry and has amassed more than 15 years experience in the drug-discovery and biotechnology industries. Most recently, he has served as Director of Chemistry at Tolero Pharmaceuticals (Lehi, Utah), an oncology-focused drug discovery company currently developing the drug Alvocidib for Leukemias. Prior to joining Tolero, he served as Director of Chemistry and Chief Scientific Officer with the small oncology drug start-up company, Frost Biologic (Salt Lake City, Utah) which culminated in the selection of a small molecule tubulin inhibitor for clinical development. Dr Siddiqui-Jain is a co-founder and serves as VP Drug Discovery at TetraGene, a start-up drug-discovery company with a technology platform that targets unusual DNA secondary structures. He previously held the position of Associate Director of Experimental Biology and Screening at Cylene Pharmaceuticals (San Diego, CA) where he was the lead project scientist on several oncology drug discovery programs. Two of these programs yielded clinical-stage candidates: Quarfloxin (phase 1 clinical trials), and CX-4945 (phase 2 clinical trials). In total, Dr Siddiqui-Jain has either lead or been integrally involved in 5 clinical stage drug discovery programs. Prior to entering the Biotechnology industry, Dr Siddiqui-Jain conducted post-doctoral research at The University of Arizona (Tucson, AZ), where he discovered a unique secondary structure in the promoter of the oncogene c-Myc. He first authored the resulting publication in The Proceedings of the National Academy of Sciences (2002), which is now seen as a seminal paper within the field and has been referenced more than 1000 times. Dr Siddiqui-Jain has more than 40 publications and patents.


David J. Bearss, PhD

Dr. David J. Bearss is a founder and member of Wasatch Scientific. Dr. Bearss currently serves as the CEO of Tolero Pharmaceuticals, a company he founded in 2011 focused on developing new treatments for patients with cancer and other life threatening diseases. Prior to founding Tolero, Dr. Bearss served as Chief Scientist and Vice President of SuperGen from 2006-2008, and was promoted to Chief Scientific Officer where he served from 2008 to 2010. Prior to this, Dr. Bearss founded Montigen Pharmaceuticals, Inc. where he built the company with outstanding scientists, developed a portfolio of target-based cancer therapeutics from discovery to IND and clinical trials, and sold the company to SuperGen (Nasdaq: SUPG) for $40 MM. He has founded and funded three start-up companies in life sciences, and has held leadership positions in academia and in the pharmaceutical industry. His expertise is in developing targeted therapeutics and has taken five products from discovery to IND. Dr. Bearss’ talent and experience includes developing extensive patent portfolios around new chemical entities and is an expert in translating science from the lab to product candidates. Dr. Bearss has more than 40 patents issued and pending and over 60 publications in scientific journals.


Steven L. Warner, PhD

Steven Warner, Ph.D., specializes in small molecule drug discovery, new screening platforms in drug discovery, and translational research focusing on cancer therapeutics. He is an expert in the discovery of novel cancer agents and has played integral roles in moving multiple compounds into clinical trials. Dr. Warner has a broad background in molecular and cell biology that comes from nearly a decade of involvement in drug discovery and development in both academic and pharmaceutical industry settings. Dr. Warner earned his graduate degree in Pharmaceutical Sciences at the University of Arizona. He completed a postdoctoral fellowship under the mentoring of Dan Von Hoff at the Translational Genomics Research Institute (TGen). In 2007, Dr. Warner joined SuperGen Inc. where he led a team of scientists focusing on studies ranging from initial compound library screens to proof-of-concept studies in animal models. Most recently, Dr. Warner has worked with the Center for Investigational Therapeutics at the Huntsman Cancer Institute as Senior Manager, Drug Discovery. Together in these capacities, he has led or integrally participated in drug discovery projects that have produced three first-in-man clinical compounds and has published several peer-reviewed publications and patents from multiple drug discovery projects.

Cory Grand, PhD

Cory hails from Saskatchewan, Canada, where he received double degrees in Biology and Microbiology/Immunology before heading south to earn his PhD in Cancer Biology through the Arizona Cancer Center at the University of Arizona in 2003. Afterward, he relocated to Salt Lake City as part of the founding team for Montigen Pharmaceuticals, a start-up drug discovery company focused on targeted small molecule development. After Montigen’s acquisition by SuperGen, Inc. in 2006, Cory moved to California to become SuperGen’s Drug Development Project Manager, receiving his PMP certification in 2008. Cory has been involved with product development in the fields of Pharmaceuticals and Biotechnology since that time, and joined Wasatch Scientific in 2015. Committed to teaching science to the non-scientific community, Cory has volunteered with the Science Ambassador program for several years, helping kids and adults alike to experience the same sense of wonder that first attracted him to biology. In his free time, Cory enjoys swing dancing, hiking, and collecting masks from around the world.